OpenAI Unveils GPT-Rosalind: A Life Science Model for Drug Discovery
OpenAI has officially launched a specialized AI model for the life sciences field - GPT-Rosalind. Named after Rosalind Franklin, the discoverer of the DNA structure, this model marks OpenAI's official entry into deep and specialized fields such as biochemistry and genomics.
Different from general language models, GPT-Rosalind has been deeply fine-tuned to meet the rigorous analytical demands of biological research. It aims to help scientists shorten the long drug development cycle, transforming tedious data analysis processes into efficient intelligent research workflows.

Exceptional scientific reasoning capabilities
GPT-Rosalind performs exceptionally well in multiple bioinformatics benchmark tests, with significantly enhanced evidence synthesis and experimental planning capabilities. It can independently retrieve specialized databases, analyze complex protein structures, and provide precise experimental pathway suggestions for cutting-edge topics such as gene therapy.
In practical collaboration with Dyno Therapeutics, the model outperformed 95% of human experts in predicting the functions of unpublished RNA sequences. This ability to reason beyond memory demonstrates the huge potential of AI in handling new biological data.

Controlled release for enterprise customers
To ensure the technology is used for legitimate scientific research that improves human health, OpenAI currently only provides access to this model for compliant enterprise customers in the United States. Several major biopharmaceutical companies, including Moderna and Amgen, have already integrated it into their drug discovery workflows.
Related article
Former OpenAI Chief Scientist Ilya’s SSI Unveils First Model
AI has achieved another major milestone. Following his departure from OpenAI, former chief scientist Ilya Sutskever established Safe Superintelligence Inc. (SSI), which has recently unveiled details regarding its inaugural model. Reports from oversea
Lovable Leads Atech's Seed Round as AI Ambient Coding Officially Enters the Hardware Field
On May 14, 2026, AI application development platform Lovable announced its participation in the $800,000 seed funding round for Danish hardware startup Atech. Led by Lovable, the round attracted top-tier venture capital firms including the a16z Scout
Anthropic Expands Claude AI Coding Tools to Japan in Push for Overseas Growth
Anthropic, a prominent U.S. artificial intelligence firm, is intensifying its global outreach. On Wednesday, the company hosted a major developer gathering, "Code with Claude," in Tokyo, drawing close to 500 software engineers. This initiative seeks
Related Special Topic Recommendations
Comments (0)
0/500
OpenAI has officially launched a specialized AI model for the life sciences field - GPT-Rosalind. Named after Rosalind Franklin, the discoverer of the DNA structure, this model marks OpenAI's official entry into deep and specialized fields such as biochemistry and genomics.
Different from general language models, GPT-Rosalind has been deeply fine-tuned to meet the rigorous analytical demands of biological research. It aims to help scientists shorten the long drug development cycle, transforming tedious data analysis processes into efficient intelligent research workflows.

Exceptional scientific reasoning capabilities
GPT-Rosalind performs exceptionally well in multiple bioinformatics benchmark tests, with significantly enhanced evidence synthesis and experimental planning capabilities. It can independently retrieve specialized databases, analyze complex protein structures, and provide precise experimental pathway suggestions for cutting-edge topics such as gene therapy.
In practical collaboration with Dyno Therapeutics, the model outperformed 95% of human experts in predicting the functions of unpublished RNA sequences. This ability to reason beyond memory demonstrates the huge potential of AI in handling new biological data.

Controlled release for enterprise customers
To ensure the technology is used for legitimate scientific research that improves human health, OpenAI currently only provides access to this model for compliant enterprise customers in the United States. Several major biopharmaceutical companies, including Moderna and Amgen, have already integrated it into their drug discovery workflows.
Former OpenAI Chief Scientist Ilya’s SSI Unveils First Model
AI has achieved another major milestone. Following his departure from OpenAI, former chief scientist Ilya Sutskever established Safe Superintelligence Inc. (SSI), which has recently unveiled details regarding its inaugural model. Reports from oversea
Lovable Leads Atech's Seed Round as AI Ambient Coding Officially Enters the Hardware Field
On May 14, 2026, AI application development platform Lovable announced its participation in the $800,000 seed funding round for Danish hardware startup Atech. Led by Lovable, the round attracted top-tier venture capital firms including the a16z Scout
Anthropic Expands Claude AI Coding Tools to Japan in Push for Overseas Growth
Anthropic, a prominent U.S. artificial intelligence firm, is intensifying its global outreach. On Wednesday, the company hosted a major developer gathering, "Code with Claude," in Tokyo, drawing close to 500 software engineers. This initiative seeks





Home






